Pyroglutamate-modified, N-terminal truncated amyloid beta (Aβ pE3 or AβN3(pE))

Pyroglutamate-modified, N-terminal truncated amyloid beta is a peptide species derived from the amyloid precursor protein (APP) through sequential enzymatic cleavage and post-translational modification. Following removal of the initial aspartic acid and alanine residues from full-length Aβ 1-42, glutaminyl cyclase catalyzes cyclization of the exposed glutamate at position 3 to generate the pyroglutamate moiety (abbreviated pE3)[2][1][6]. This modified peptide, most commonly denoted Aβ pE3-42, forms more stable, hydrophobic, and aggregation-prone oligomers and fibrils than full-length Aβ. Pyroglutamate Aβ peptides account for 15-45% of total amyloid beta in Alzheimer’s disease plaques and are strongly implicated in disease pathogenesis because of their toxicity, resistance to enzymatic degradation, and ability to seed amyloid aggregation[1][2][4]. Emerging therapies target these species with monoclonal antibodies or by inhibiting the enzyme glutaminyl cyclase to reduce pE3-Aβ formation, aiming to halt or slow Alzheimer’s-related neurodegeneration[1][5][7]. Plasma levels of pE3 Aβ are explored as biomarkers for diagnosis and progression monitoring in Alzheimer’s disease[8].

Other names

Pyroglutamate amyloid betaPyroglutamate Aβ 3-42Aβ pE3-42AβN3(pE)Pyroglutamate AβPyro AβPyroglutamate-modified Aβ peptideBeta amyloid peptide 3-42 (pE3)Aβ3(pE)-42

Antibodies: Neutralization of Aβ pE3 oligomers and prevention of fibril formation[7] QC inhibitors: Blockage of pyroglutamate formation at the Aβ N-terminus, reducing pE3-Aβ production and aggregation[5][1]